Delivery Order SPE2DB22D3004-SPE2DB25FSF42
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,424.55. This competitive award, issued under a firm fixed-price delivery order contract type, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The order does not utilize a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $6,072.14. This is a firm fixed-price delivery order issued without set-aside provisions, indicating competitive award to a qualified vendor. The contract is performed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 25, 2025. This delivery...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of NovoLog 100 Unit/ML vial 10ML insulin medication. This is a firm fixed-price delivery order with a ceiling value of $7,929.22 and an ultimate completion date of August 28, 2025. The contract is not set-aside and was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, reflecting the...
- The Defense Logistics Agency awarded a $2,737.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL). The contract, which is a child order under a larger indefinite delivery contract, carries an ultimate completion date of August 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a non-competitive, competitively awarded transaction...
- The Defense Logistics Agency awarded a delivery order valued at $4,819.02 to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). The contract, classified as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was made through open competition with no set-aside designation. This delivery order is issued...
- The Defense Logistics Agency awarded a $2,045.20 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) to be delivered by July 29, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating open competitive procurement. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with a firm fixed price ceiling value of $7,959.91. The order, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a non-competitive delivery order under AmerisourceBergen's existing indefinite delivery contract vehicle with DLA. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $3,648.07. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to the prime contractor. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 24, 2025. This delivery order falls under...
- The Defense Logistics Agency awarded a $6,102.42 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on July 30, 2025, with a completion date of July 31, 2025. This is a firm fixed price, non-set-aside contract to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL vials (10mL) with a ceiling value of $1,243.75. This is a firm fixed price delivery order with no set-aside designation, executed as a competitive award through the company's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSF42Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a ceiling value of $1,040.41. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 29, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at approximately $1 billion through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The NovoLog insulin delivery under this order supports the Defense Health Agency's pharmaceutical supply needs for military medical facilities and personnel. The company's extensive federal contract portfolio demonstrates its capability to supply a comprehensive range of pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains through competitive procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 8/28/25 |